CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Icagen, Inc. (Old) is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Icagen, Inc. (Old)
4222 Emperor Boulevard,
Suit 350
Phone: (919) 941-5206p:919 941-5206 Durham, NC  27703  United States Fax: (919) 941-0813f:919 941-0813

This company was Merged or Acquired on 10/28/2011.
This company ceased filing statements with the SEC on 11/7/2011.
On July 1, 2015, XRPro Sciences, Inc., now known as Icagen Inc., consummated its purchase of certain assets of Icagen Inc., a wholly owned subsidiary of Pfizer Inc., including certain cell lines, office equipment, servers, biology instruments, benchtops and the Icagen name. The Company agreed to pay: (i) an upfront cash purchase price of $500,000, of which $125,000 was paid at closing date, and $375,000 is to be paid in three equal installments of $125,000, on September 1, 2015, December 1, 2015 and March 1, 2016; (ii) a cash payment of $500,000 on the second anniversary of the closing provided that prior to such date the Master Scientific Services Agreement has generated at least $4,000,000 in revenue; and (iii) beginning in 2017, a quarterly earn out payment of 10% of revenue earned during the quarter up to a maximum aggregate payment of $10,000,000. The Company also assumed certain liabilities of Icagen and agreed to continue the employment of several employees of Icagen for at least two years.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company

Business Summary
Icagen, Inc. (Icagen) is a biopharmaceutical company focused on the discovery, development and commercialization of orally-administered small molecule drugs that modulate ion channel targets. The Company’s principal program is ICA-105665 for epilepsy and pain, for which the Company has completed a proof-of-concept trial in epilepsy with positive results and a proof-of-concept trial in pain with negative results. The Company is also conducting ongoing drug discovery programs focused on new therapeutics for pain and inflammatory disorders. In each of these programs, it has identified small molecule compounds that have demonstrated activity on specific ion channels. In October 2011, Pfizer Inc. acquired Icagen.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
6/30/201112/31/2010YesYes--Yes

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chief Executive Officer P. KayWagoner 62 10/27/2011 1/1/1992
President RuthMckernan 53 10/27/2011 9/22/2011
Chief Financial Officer, Executive Vice President - Finance, Executive Vice President Richard D.Katz 47 10/27/2011 4/1/2001
6 additional Officers and Directors records available in full report.

General Information
Stock Exchange: NASD
Federal Tax Id: 561785001
Fax Number: (919) 941-0813


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023